<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39421662</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2575-9108</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>ACS pharmacology &amp; translational science</Title><ISOAbbreviation>ACS Pharmacol Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease.</ArticleTitle><Pagination><StartPage>3170</StartPage><EndPage>3191</EndPage><MedlinePgn>3170-3191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsptsci.4c00369</ELocationID><Abstract><AbstractText>Although the coronavirus disease 2019 (COVID-19) crisis has passed, there remains a necessity for continuous efforts toward developing more targeted drugs and preparing for potential future virus attacks. Currently, most of the drugs received authorization for the treatment of COVID-19 have exhibited several limitations, such as poor metabolic stability, formidable preparation, and uncertain effectiveness. It is still significant to develop novel, structurally diverse small-molecule antiviral drugs targeting SARS-CoV-2 3-chymotrypsin-like protease (3CL<sup>pro</sup>). Herein, we report a class of alkynylamide-based nonpeptidic 3CL<sup>pro</sup> inhibitors that can be prepared conveniently by our previously developed one-pot synthetic method. The structure-activity relationships of alkynylamides as SARS-CoV-2 3CL<sup>pro</sup> inhibitors have been carefully investigated and discussed in this study. The two stereoisomers of the resulting molecules exhibit stereoselective interaction with 3CL<sup>pro</sup>, and the optimized compound (<i>S</i>,<i>R</i>)-<b>4y</b> inhibits 3CL<sup>pro</sup> with high potency (IC<sub>50</sub> = 0.43 μM), low cytotoxicity, and acceptable cell permeability. Compound (<i>S</i>,<i>R</i>)-<b>4y</b> presents as a noncovalent inhibitor of 3CL<sup>pro</sup> against SARS-CoV-2 by the time-dependent inhibition assay (TDI) and mass spectrometry analysis. The Lineweaver-Burk plots, binding energy, surface plasmon resonance, and molecular docking studies suggest that (<i>S</i>,<i>R</i>)-<b>4y</b> specifically binds to an allosteric pocket of the SARS-CoV-2 3CL<sup>pro</sup>. These findings provide a novel class of nonpeptidic alkynylamide-based allosteric inhibitors with high selectivity against SARS-CoV-2 3CL<sup>pro</sup> featured by a simplified one-pot synthesis at room temperature in air.</AbstractText><CopyrightInformation>© 2024 American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongtao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruyu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meiting</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xixiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Academy of Integrative Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yaqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiani</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yexi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jianrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academy of Integrative Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7472-3736</Identifier><AffiliationInfo><Affiliation>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shunying</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3894-757X</Identifier><AffiliationInfo><Affiliation>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Pharmacol Transl Sci</MedlineTA><NlmUniqueID>101721411</NlmUniqueID><ISSNLinking>2575-9108</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39421662</ArticleId><ArticleId IdType="pmc">PMC11481521</ArticleId><ArticleId IdType="doi">10.1021/acsptsci.4c00369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P.; Yang X. L.; Wang X. G.; Hu B.; Zhang L.; Zhang W.; Si H. R.; Zhu Y.; Li B.; Huang C. L.; Chen H. D.; Chen J.; Luo Y.; Guo H.; Jiang R. D.; Liu M. Q.; Chen Y.; Shen X. R.; Wang X.; Zheng X. S.; Zhao K.; Chen Q. J.; Deng F.; Liu L. L.; Yan B.; Zhan F. X.; Wang Y. Y.; Xiao G. F.; Shi Z. L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F.; Zhao S.; Yu B.; Chen Y. M.; Wang W.; Song Z. G.; Hu Y.; Tao Z. W.; Tian J. H.; Pei Y. Y.; Yuan M. L.; Zhang Y. L.; Dai F. H.; Liu Y.; Wang Q. M.; Zheng J. J.; Xu L.; Holmes E. C.; Zhang Y. Z. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269. 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Amblard F.; LeCher J. C.; De R. Y.; Zhou S. M.; Liu P.; Goh S. L.; Tao S. J.; Patel D.; Downs-Bowen J.; Zandi K.; Zhang H. C.; Chaudhry G.; McBrayer T.; Muczynski M.; Al-Homoudi A.; Engel J.; Lan S. Y.; Sarafianos S. G.; Kovari L. C.; Schinazi R. F. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease. Eur. J. Med. Chem. 2024, 268, 116263–116271. 10.1016/j.ejmech.2024.116263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2024.116263</ArticleId><ArticleId IdType="pmc">PMC11188152</ArticleId><ArticleId IdType="pubmed">38432056</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y.; Zhang M.; Yin L.; Wang K.; Zhou Y.; Zhou M.; Lu Y. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int. J. Antimicrob. Agents 2020, 56, 106080.10.1016/j.ijantimicag.2020.106080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106080</ArticleId><ArticleId IdType="pmc">PMC7334905</ArticleId><ArticleId IdType="pubmed">32634603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P.; Mohammadi-Samani S. COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart Lung 2020, 49, 763–773. 10.1016/j.hrtlng.2020.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7500907</ArticleId><ArticleId IdType="pubmed">32980626</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W. H.; Zhang B.; Jiang X. M.; Su H.; Li J.; Zhao Y.; Xie X.; Jin Z.; Peng J.; Liu F.; et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020, 368, 1331–1335. 10.1126/science.abb4489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A.; Chan J. F. W.; Azhar E. I.; Hui D. S. C.; Yuen K. Y. Coronaviruses-drug discovery and therapeutic options. Nat. Rev. Drug Discovery 2016, 15, 327–347. 10.1038/nrd.2015.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2015.37</ArticleId><ArticleId IdType="pmc">PMC7097181</ArticleId><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire R.; Cerchia C.; Beccari A. R.; Di Leva F. S.; Summa V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J. Med. Chem. 2022, 65, 2716–2746. 10.1021/acs.jmedchem.0c01140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01140</ArticleId><ArticleId IdType="pmc">PMC7688049</ArticleId><ArticleId IdType="pubmed">33186044</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Zhao Y.; Zhang B.; Li X.; Zhang L.; Peng C.; Duan Y.; Yu J.; Wang L.; Yang K.; Liu F.; Jiang R.; Yang X.; You T.; Liu X.; Yang X.; Bai F.; Liu H.; Liu X.; Guddat L. W.; Xu W.; Xiao G.; Qin C.; Shi Z.; Jiang H.; Rao Z.; Yang H. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582, 289–293. 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang R.; Yu Z.; Wang Y.; Wang L.; Huo S.; Li Y.; Liang R.; Hao Q.; Ying T.; Gao Y.; Yu F.; Jiang S. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm. Sin. B 2022, 12, 1591–1623. 10.1016/j.apsb.2021.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.06.016</ArticleId><ArticleId IdType="pmc">PMC8260826</ArticleId><ArticleId IdType="pubmed">34249607</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno S.; Kobayashi K.; Senda M.; Funai Y.; Seki Y.; Tamai I.; Schäkel L.; Sakata K.; Pillaiyar T.; Taguchi A.; Taniguchi A.; Gütschow M.; Müller C. E.; Takeuchi K.; Hirohama M.; Kawaguchi A.; Kojima M.; Senda T.; Shirasaka Y.; Kamitani W.; Hayashi Y. 3CL protease inhibitors with an electrophilic arylketone moiety as Anti-SARS-CoV-2 agents. J. Med. Chem. 2022, 65, 2926–2939. 10.1021/acs.jmedchem.1c00665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00665</ArticleId><ArticleId IdType="pubmed">34313428</ArticleId></ArticleIdList></Reference><Reference><Citation>Breidenbach J.; Lemke C.; Pillaiyar T.; Schakel L.; Al Hamwi G.; Diett M.; Gedschold R.; Geiger N.; Lopez V.; Mirza S.; Namasivayam V.; Schiedel A. C.; Sylvester K.; Thimm D.; Vielmuth C.; Phuong Vu L.; Zyulina M.; Bodem J.; Gutschow M.; Muller C. E. Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors. Angew. Chem., Int. Ed. 2021, 60, 10423–10429. 10.1002/anie.202016961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202016961</ArticleId><ArticleId IdType="pmc">PMC8014119</ArticleId><ArticleId IdType="pubmed">33655614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R. L.; Kania R. S.; Brothers M. A.; Davies J. F.; Ferre R. A.; Gajiwala K. S.; He M.; Hogan R. J.; Kozminski K.; Li L. Y.; Lockner J. W.; Lou J.; Marra M. T.; Mitchell L. J. Jr.; Murray B. W.; Nieman J. A.; Noell S.; Planken S. P.; Rowe T.; Ryan K.; Smith G. J. 3rd; Solowiej J. E.; Steppan C. M.; Taggart B. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 2020, 63, 12725–12747. 10.1021/acs.jmedchem.0c01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01063</ArticleId><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dampalla C. S.; Kim Y.; Bickmeier N.; Rathnayake A. D.; Nguyen H. N.; Zheng J.; Kashipathy M. M.; Baird M. A.; Battaile K. P.; Lovell S.; Perlman S.; Chang K. O.; Groutas W. C. Structure-Guided design of conformationally constrained cyclohexane inhibitors of severe acute respiratory syndrome coronavirus-2 3CL protease. J. Med. Chem. 2021, 64, 10047–10058. 10.1021/acs.jmedchem.1c00319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00319</ArticleId><ArticleId IdType="pmc">PMC8276672</ArticleId><ArticleId IdType="pubmed">34213885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P. G.; Li H.; Nie T. Q.; Jian X. Q.; Yu C. Y.; Li J.; Su H. X.; Zhang X. L.; Li S. W.; Yang X.; Peng C.; Yin Y.; Zhang L. K.; Xu Y. C.; Liu H.; Bai F. Discovery and mechanism study of SARS-CoV-2 3C-like protease inhibitors with a new reactive group. J. Med. Chem. 2023, 66, 12266–12283. 10.1021/acs.jmedchem.3c00818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.3c00818</ArticleId><ArticleId IdType="pubmed">37594952</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres C. J.; Cardenas-Garcia S.; Carnaccini S.; Seibert B.; Rajao D. S.; Wang J.; Perez D. R. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci. Rep. 2021, 11, 9609–9622. 10.1038/s41598-021-89013-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89013-w</ArticleId><ArticleId IdType="pmc">PMC8100161</ArticleId><ArticleId IdType="pubmed">33953295</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K. C.; Ziebuhr J.; Wadhwani P.; Mesters J. R.; Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763–1767. 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B.; Jones R. M.; Anson B. J.; Arenson D.; Aschenbrenner L.; Bakowski M. A.; Beutler N.; Binder J.; Chen E.; Eng H.; Hammond H.; Hammond J.; Haupt R. E.; Hoffman R.; Kadar E. P.; Kania R.; Kimoto E.; Kirkpatrick M. G.; Lanyon L.; Lendy E. K.; Lillis J. R.; Logue J.; Luthra S. A.; Ma C.; Mason S. W.; McGrath M. E.; Noell S.; Obach R. S.; O’ Brien M. N.; O’Connor R.; Ogilvie K.; Owen D.; Pettersson M.; Reese M. R.; Rogers T. F.; Rosales R.; Rossulek M. I.; Sathish J. G.; Shirai N.; Steppan C.; Ticehurst M.; Updyke L. W.; Weston S.; Zhu Y.; White K. M.; Garcia-Sastre A.; Wang J.; Chatterjee A. K.; Mesecar A. D.; Frieman M. B.; Anderson A. S.; Allerton C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 2021, 12, 6055–6072. 10.1038/s41467-021-26239-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26239-2</ArticleId><ArticleId IdType="pmc">PMC8523698</ArticleId><ArticleId IdType="pubmed">34663813</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D. R.; Allerton C. M. N.; Anderson A. S.; Aschenbrenner L.; Avery M.; Berritt S.; Boras B.; Cardin R. D.; Carlo A.; Coffman K. J.; et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021, 374, 1586–1593. 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. X.; Huang X. D.; Ma Q. H.; Kuzmič P.; Zhou B.; Zhang S.; Chen J. Z.; Xu J. X.; Liu B.; Jiang H. M.; Zhang W. J.; Yang C. J.; Wu S. G.; Huang J. Z.; Li H. J.; Long C. F.; Zhao X.; Xu H. R.; Sheng Y. N.; Guo Y. T.; Niu C. Y.; Xue L.; Xu Y.; Liu J. S.; Zhang T. Y.; Spencer J.; Zhu Z. Z.; Deng W. B.; Chen X. W.; Chen S. H.; Zhong N. S.; Xiong X. L.; Yang Z. F. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat. Microbiol. 2024, 9, 1075–1088. 10.1038/s41564-024-01618-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-024-01618-9</ArticleId><ArticleId IdType="pmc">PMC10994847</ArticleId><ArticleId IdType="pubmed">38553607</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X.; Su H. X.; Shang W. J.; Zhou F.; Zhang Y.; Zhao W. F.; Zhang Q. M.; Xie H.; Jiang L.; Nie T. Q.; Yang F. P.; Xiong M. Y.; Huang X. X.; Li M. J.; Chen P.; Peng S. P.; Xiao G. F.; Jiang H. L.; Tang R. H.; Zhang L. K.; Shen J. S.; Xu Y. C. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 2023, 14, 6463.10.1038/s41467-023-42102-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42102-y</ArticleId><ArticleId IdType="pmc">PMC10575921</ArticleId><ArticleId IdType="pubmed">37833261</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.-W.; Xiong Y.; Wang F.; Zhang F. M.; Yang X.; Lin G. Q.; Tian P.; Ge G.; Gao D. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL(pro) inhibitors for treating COVID-19. Eur. J. Med. Chem. 2022, 228, 114030.10.1016/j.ejmech.2021.114030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.114030</ArticleId><ArticleId IdType="pmc">PMC8634693</ArticleId><ArticleId IdType="pubmed">34883292</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y.; Uehara S.; Nakahara K.; Nobori H.; Yamatsu Y.; Yamamoto S.; Maruyama Y.; Taoda Y.; Kasamatsu K.; Suto T.; Kouki K.; Nakahashi A.; Kawashima S.; Sanaki T.; Toba S.; Uemura K.; Mizutare T.; Ando S.; Sasaki M.; Orba Y.; Sawa H.; Sato A.; Sato T.; Kato T.; Tachibana Y. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 2022, 65, 6499–6512. 10.1021/acs.jmedchem.2c00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00117</ArticleId><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Drayman N.; Jones K. A.; Azizi S. A.; Froggatt H. M.; Tan K.; Maltseva N. I.; Chen S.; Nicolaescu V.; Dvorkin S.; Furlong K.; Kathayat R. S.; Firpo M. R.; Mastrodomenico V.; Bruce E. A.; Schmidt M. M.; Jedrzejczak R.; MunozAlia M. A.; Schuster B.; Nair V.; Botten J. W.; Brooke C. B.; Baker S. C.; Mounce B. C.; Heaton N. S.; Dickinson B. C.; Jaochimiak A.; Randall G.; Tay S. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro. bioRxiv 2020, 5827–5859. 10.1101/2020.08.31.274639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.31.274639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S.; Sylvester K.; Song L.; Claff T.; Jing L.; Woodson M.; Weiße R. H.; Cheng Y.; Schäkel L.; Petry M.; Gütschow M.; Schiedel A. C.; Sträter N.; Kang D.; Xu S.; Toth K.; Tavis J.; Tollefson A. E.; Müller C. E.; Liu X.; Zhan P. Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity. J. Med. Chem. 2022, 65, 13343–13364. 10.1021/acs.jmedchem.2c01146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01146</ArticleId><ArticleId IdType="pubmed">36107752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W.; Xu M.; Chen C. Z.; Guo H.; Shen M.; Hu X.; Shinn P.; Klumpp-Thomas C.; Michael S. G.; Zheng W. Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening. ACS Pharmacol. Transl. Sci. 2020, 3, 1008–1016. 10.1021/acsptsci.0c00108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00108</ArticleId><ArticleId IdType="pmc">PMC7507806</ArticleId><ArticleId IdType="pubmed">33062953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z.; Feng B.; Zhang Y.; Nie T.; Liu H.; Li J.; Su H.; Zhang L.; Zang Y.; Zhou Y. Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment. Signal Transduction Targeted Ther. 2023, 8, 209.10.1038/s41392-023-01482-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01482-9</ArticleId><ArticleId IdType="pmc">PMC10201506</ArticleId><ArticleId IdType="pubmed">37217487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou N. K.; Shuai L.; Zhang L. J.; Xie X. P.; Tang K. M.; Zhu Y. K.; Yu Y.; Zhang W. Y.; Tan Q. Z.; Zhong G. X.; Wen Z. Y.; Wang C.; He X. J.; Huo H.; Gao H. H.; Xu Y.; Xue J.; Peng C.; Zou J.; Schindewolf C.; Menachery V.; Su W. J.; Yuan Y. L.; Shen Z. Y.; Zhang R.; Yuan S. F.; Yu H. T.; Shi P. Y.; Bu Z. G.; Huang J.; Hu Q. Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro. ACS Cent. Sci. 2023, 9, 217–227. 10.1021/acscentsci.2c01359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.2c01359</ArticleId><ArticleId IdType="pmc">PMC9885526</ArticleId><ArticleId IdType="pubmed">36844503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.-J.; Chen W. C.; Kuo T. F.; Yang G.; Feng C. S.; Chen H. M.; Chen T. Y.; Lee T. H.; Yang W. C.; Tsai K. C.; et al. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice. Cell. Mol. Life Sci. 2023, 80, 101.10.1007/s00018-022-04677-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04677-5</ArticleId><ArticleId IdType="pmc">PMC10025235</ArticleId><ArticleId IdType="pubmed">36935456</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W. H.; Zhang B.; Jiang X. M.; Su H. X.; Li J.; Zhao Y.; Xie X.; Jin Z. M.; Peng J. J.; Liu F. J.; Li C. P.; Li Y.; Bai F.; Wang H. F.; Cheng X.; Cen X. B.; Hu S. L.; Yang X. N.; Wang J.; Liu X.; Xiao G. F.; Jiang H. L.; Rao Z. H.; Zhang L. K.; Xu Y. C.; Yang H. T.; Liu H. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020, 368, 1331–1335. 10.1126/science.abb4489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D. G.; Boström J. Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?. J. Med. Chem. 2016, 59, 4443–4458. 10.1021/acs.jmedchem.5b01409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01409</ArticleId><ArticleId IdType="pubmed">26571338</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.; Guo X.; Jin W.; Zheng Q.; Liu S.; Hu W.; Hu W. H. An enantioselective three-component reaction of diazoacetates with indoles and enals by iridi-um/iminium co-catalysis. Chem. Commun. 2016, 52, 2736.10.1039/c5cc09918h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c5cc09918h</ArticleId><ArticleId IdType="pubmed">26758486</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue J.; Luo Z. L.; Huang J. S.; Deng Y. Q.; Dong S. Z.; Liu S. Y. Enantioselective Construction of C3-Multifunctionalization α-Hydroxy-β-amino Pyridines via α-Pyridyl Diazoacetate, Water, and Imines for Drug Hunting. Org. Lett. 2022, 24, 9502–9507. 10.1021/acs.orglett.2c03987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.orglett.2c03987</ArticleId><ArticleId IdType="pubmed">36537781</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Z. L.; Chen X.; Xue J.; Deng Y.; Dong S.; Liu S. Y. Efficient synthesis of benzosultams containing continuous quaternary carbons via trapping active ylides with cyclic N-sulfonyl ketimines. Org. Chem. Front. 2022, 9, 6592–6597. 10.1039/D2QO01409B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2QO01409B</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L.; Xiong L.; Ni D.; Chen W.; Ji J.; Xue J.; Chen X.; Wu X.; He X.; Liu S. One-Pot Construction of β-Selective Quinolines with γ-Quaternary Carbon from Vinylquinolines with Active Ylides via Pd/Sc/Brønsted Acid Co-Catalysis. ACS Catal. 2023, 13, 6509–6517. 10.1021/acscatal.2c05824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscatal.2c05824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J.-J.; Zhu S.; Cai Y.; Xu H.; Xie X.; Zhou Q. L. Enantioselective Iron-Catalyzed Intramolecular Cyclopropanation Reactions. Angew. Chem., Int. Ed. 2014, 53, 13188–13191. 10.1002/anie.201406853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201406853</ArticleId><ArticleId IdType="pubmed">25283384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei R.; Wu Y.; Dong S.; Jia K.; Liu S.; Hu W. H. A Diastereoselective Multicomponent Reaction for Construction of Alkynylamide-Substituted α,β-Diamino Acid Derivatives To Hunt Hits. J. Org. Chem. 2017, 82, 2862–2869. 10.1021/acs.joc.6b02761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.joc.6b02761</ArticleId><ArticleId IdType="pubmed">28225272</ArticleId></ArticleIdList></Reference><Reference><Citation>Guptill D. M.; Davies H. M. L. 2,2,2-Trichloroethyl aryldiazoacetates as robust reagents for the enantioselective C-H functionalization of methyl ethers. J. Am. Chem. Soc. 2014, 136, 17718–17721. 10.1021/ja5107404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja5107404</ArticleId><ArticleId IdType="pubmed">25474724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitani H.; Komiyama S.; Hasegawa Y.; Kobayashi S. Catalytic Asymmetric Strecker Synthesis. Preparation of Enantiomerically Pure α-Amino Acid Derivatives from Aldimines and Tributyltin Cyanide or Achiral Aldehydes, Amines, and Hydrogen Cyanide Using a Chiral Zirconium Catalyst. J. Am. Chem. Soc. 2000, 122, 762–766. 10.1021/ja9935207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9935207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K.; Dong S.; Xu X.; Zhang Z.; Shi T.; Yuan H.; Xu X.; Hu W. Enantioselective Intermolecular Mannich-type Interception of Phenolic Oxonium Ylide for the Direct Assembly of Chiral 2,2-Disubstituted dihydrobenzofurans. ACS Catal. 2021, 11, 6750–6756. 10.1021/acscatal.1c01321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscatal.1c01321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R. Y.; Hu Q.; Wang H.; Zhu G.; Wang M.; Zhang Q.; Zhao Y.; Li C.; Zhang Y.; Ge G.; et al. Identification of vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. Int. J. Biol. Macromol. 2021, 183, 182–192. 10.1016/j.ijbiomac.2021.04.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2021.04.129</ArticleId><ArticleId IdType="pmc">PMC8064871</ArticleId><ArticleId IdType="pubmed">33901557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R.; Chen X. W.; Li H. T.; Chen X.; Sun D. H.; Yu D.; Lu J.; Xie Y.; Zhang Q.; Xu J.; et al. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting anti-viral and anti-inflammatory activity. Int. J. Biol. Macromol. 2024, 257, 128623.10.1016/j.ijbiomac.2023.128623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2023.128623</ArticleId><ArticleId IdType="pubmed">38070810</ArticleId></ArticleIdList></Reference><Reference><Citation>Krippendorff B. F.; Neuhaus R.; Lienau P.; Reichel A.; Huisinga W. Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC50 values. J. Biomol. Screening 2009, 14, 913–923. 10.1177/1087057109336751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057109336751</ArticleId><ArticleId IdType="pubmed">19675314</ArticleId></ArticleIdList></Reference><Reference><Citation>Samrat S. K.; Xu J.; Xie X.; Gianti E.; Chen H.; Zou J.; Pattis J. G.; Elokely K.; Lee H.; Li Z.; Klein M. L.; Shi P. Y.; Zhou J.; Li H. Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Res. 2022, 205, 105381.10.1016/j.antiviral.2022.105381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105381</ArticleId><ArticleId IdType="pmc">PMC9272661</ArticleId><ArticleId IdType="pubmed">35835291</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther S.; Reinke P. Y. A.; Fernández-García Y.; Lieske J.; Lane T. J.; Ginn H. M.; Koua F. H. M.; Ehrt C.; Ewert W.; Oberthuer D.; Yefanov O.; Meier S.; Lorenzen K.; Krichel B.; Kopicki J. D.; Gelisio L.; Brehm W.; Dunkel I.; Seychell B.; Gieseler H.; Norton-Baker B.; Escudero-Pérez B.; Domaracky M.; Saouane S.; Tolstikova A.; White T. A.; Hänle A.; Groessler M.; Fleckenstein H.; Trost F.; Galchenkova M.; Gevorkov Y.; Li C.; Awel S.; Peck A.; Barthelmess M.; Schlünzen F.; Lourdu Xavier P.; Werner N.; Andaleeb H.; Ullah N.; Falke S.; Srinivasan V.; França B. A.; Schwinzer M.; Brognaro H.; Rogers C.; Melo D.; Zaitseva-Doyle J. J.; Knoska J.; Peña-Murillo G. E.; Mashhour A. R.; Hennicke V.; Fischer P.; Hakanpää J.; Meyer J.; Gribbon P.; Ellinger B.; Kuzikov M.; Wolf M.; Beccari A. R.; Bourenkov G.; von Stetten D.; Pompidor G.; Bento I.; Panneerselvam S.; Karpics I.; Schneider T. R.; Garcia-Alai M. M.; Niebling S.; Günther C.; Schmidt C.; Schubert R.; Han H.; Boger J.; Monteiro D. C. F.; Zhang L.; Sun X.; Pletzer-Zelgert J.; Wollenhaupt J.; Feiler C. G.; Weiss M. S.; Schulz E. C.; Mehrabi P.; Karničar K.; Usenik A.; Loboda J.; Tidow H.; Chari A.; Hilgenfeld R.; Uetrecht C.; Cox R.; Zaliani A.; Beck T.; Rarey M.; Günther S.; Turk D.; Hinrichs W.; et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 2021, 372, 642–646. 10.1126/science.abf7945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.; Sacco M. D.; Hurst B.; Townsend J. A.; Hu Y.; Szeto T.; Zhang X.; Tarbet B.; Marty M. T.; Chen Y.; Wang J. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research 2020, 30, 678–692. 10.1038/s41422-020-0356-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G. M.; Huey R.; Lindstrom W.; Sanner M. F.; Belew R. K.; Goodsell D. S.; Olson A. J. Autodock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30, 2785–2791. 10.1002/jcc.21256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21256</ArticleId><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.; Xia Z.; Sacco M. D.; Hu Y.; Townsend J. A.; Meng X.; Choza J.; Tan H.; Jang J.; Gongora M. V.; Zhang X.; Zhang F.; Xiang Y.; Marty M. T.; Chen Y.; et al. Discovery of Di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J. Am. Chem. Soc. 2021, 143, 20697–20709. 10.1021/jacs.1c08060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.1c08060</ArticleId><ArticleId IdType="pmc">PMC8672434</ArticleId><ArticleId IdType="pubmed">34860011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukassen S.; Chua R. L.; Trefzer T.; Kahn N. C.; Schneider M. A.; Muley T.; Winter H.; Meister M.; Veith C.; Boots A. W.; Hennig B. P.; Kreuter M.; Conrad C.; Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020, 39, e10511410.15252/embj.20105114.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.20105114</ArticleId><ArticleId IdType="pmc">PMC7232010</ArticleId><ArticleId IdType="pubmed">32246845</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C. B.; Farzan M.; Chen B.; Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022, 23, 3–20. 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer. Exp. Mol. Med. 2023, 55, 716–724. 10.1038/s12276-023-00975-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-00975-5</ArticleId><ArticleId IdType="pmc">PMC10167312</ArticleId><ArticleId IdType="pubmed">37009799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.; Murawski A.; Patel K.; Crespi C. L.; Balimane P. V. A novel design of artificial membrane for improving the PAMPA model. Pharm. Res. 2008, 25, 1511–1520. 10.1007/s11095-007-9517-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-007-9517-8</ArticleId><ArticleId IdType="pubmed">18185985</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>